Welcome to our dedicated page for STANDARD BIOTOOLS SEC filings (Ticker: LAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Standard BioTools Inc. filings document the regulatory record for a life-science research tools company centered on mass cytometry, microfluidics, genomics, single-cell proteomics and spatial proteomics. Current reports cover operating results, revenue outlook disclosures, restructuring and cost-savings actions, capital-structure changes, material agreements and risk factors tied to its research-use instrument, consumable and service portfolio.
Proxy materials describe board elections, executive compensation votes, auditor ratification, equity incentive plan approvals and employee stock purchase plan amendments. Form 8-K filings also record material events such as the completed SomaLogic sale, related financial disclosures, shareholder voting matters and Nasdaq continued-listing compliance notices.
Standard BioTools Inc. entered into an Agreement and Plan of Merger and Reorganization to combine with Treeline Biosciences, Inc. in an all‑stock merger. The Exchange Ratio ties to an assumed Treeline equity value of $2.5 billion and an assumed Standard BioTools equity value of $460 million, with former Standard BioTools stockholders expected to hold approximately 16% of the combined company on a fully diluted basis and former Treeline stockholders approximately 84%.
The Merger contemplates a Charter Amendment to change the company name to Treeline Biosciences Holdings, Inc., a possible Reverse Stock Split, assumption of Treeline equity awards and warrants, a CVR program with a maximum 76,000,000 shares available, customary closing conditions (including stockholder approvals, Form S-4 effectiveness and HSR clearance), a $16.1 million termination payment in specified circumstances and reimbursement of Treeline out-of-pocket fees up to $5 million. Standard BioTools expects closing in the second half of 2026.
Standard BioTools Inc. agreed to an all-stock merger with privately held Treeline Biosciences, creating a combined company focused on Treeline’s clinical-stage drug pipeline. Treeline will become a wholly owned subsidiary and the parent will be renamed Treeline Biosciences Holdings, Inc., with a potential reverse stock split at closing.
The deal values Treeline at $2.5 billion and Standard BioTools at about $460 million, based on net cash. On a fully diluted basis, former Standard BioTools stockholders are expected to own roughly 16% of the combined company and former Treeline holders about 84%, with final percentages adjusted to Standard BioTools’ net cash at closing.
Standard BioTools must seek stockholder approval for issuing new shares, amending its charter and adopting new equity plans, and must pursue monetization or wind-down of its mass cytometry and microfluidics businesses. Legacy stockholders are expected to receive one contingent value right per share, with potential payments in stock over five years tied to net proceeds from divesting legacy assets and certain existing investments, up to a maximum of 76,000,000 shares. The combined company is expected to have more than $900 million in cash at closing, with runway projected into 2029, and will be led by Treeline’s management team.
Standard BioTools Inc. has regained compliance with Nasdaq’s minimum bid price rule. On June 5, 2026, the company received notice from Nasdaq’s Listing Qualifications Staff confirming that it now meets Nasdaq Listing Rule 5450(a)(1), which requires a bid price of at least $1.00 per share. The issue arose after an April 20, 2026 notice that the company’s common stock had closed below $1.00 for 30 consecutive business days. Nasdaq has now closed this matter, and the company’s common stock continues to trade on the Nasdaq Global Select Market under the symbol LAB.
Standard BioTools Inc. approved a grant of 500,000 restricted stock units to Chief Business Officer Sean Mackay under its 2026 Equity Incentive Plan, effective June 20, 2026. If he continues providing services, 40% of the award will vest on June 20, 2027 and the remaining 60% on June 20, 2028. The award is governed by the 2026 Equity Incentive Plan, its RSU agreement, and the company’s 2026 Change of Control and Severance Plan and related participation agreement.
Standard BioTools Inc. approved new and updated executive severance plans that define cash, equity and benefit protections upon certain terminations and change of control events. The 2026 Change of Control and Severance Plan, effective through August 4, 2028, covers the executive leadership team other than the CEO, with Alex Kim (CFO) and Sean MacKay (Chief Business Officer) entering participation agreements.
Outside a change of control period, covered executives may receive 100% of annual base salary over 12 months, a pro-rated target bonus, up to 12 months of health coverage reimbursement, potential accelerated equity vesting for terminations on or before August 27, 2026, and outplacement services. If terminated within a defined change of control period, they may receive a lump sum equal to 150% of salary plus specified bonus metrics, a pro-rated target bonus, up to 18 months of health coverage reimbursement, and full equity acceleration.
The Board also approved an amended and restated 2023 Change of Control and Severance Plan for CEO Michael Egholm, Ph.D., as sole participant, with an initial term through August 4, 2028. Outside a change of control period, the CEO is eligible for 200% of base salary over 24 months, up to 12 months of health coverage reimbursement and outplacement services. If terminated within a change of control period, the CEO may receive a lump sum equal to 250% of salary plus specified bonus metrics, a pro-rated target bonus, up to 30 months of health coverage reimbursement, and full acceleration of unvested equity awards.
STANDARD BIOTOOLS INC. Chief Financial Officer Hanjoon Alex Kim reported a routine tax-related share disposition. On May 20, 2026, 18,871 shares of common stock were withheld to cover tax obligations from vesting restricted stock units. After this non-market transaction, he directly holds 2,760,530 shares.
STANDARD BIOTOOLS INC. senior vice president and chief business officer Sean Mackay reported a routine tax-withholding transaction. On May 20, 2026, 25,729 shares of common stock were withheld to satisfy tax obligations arising from vested restricted stock units granted on May 20, 2024, March 21, 2025 and March 20, 2026.
Following this withholding, Mackay directly holds 1,006,552 shares of common stock. This Form 4 reflects compensation-related tax settlement rather than an open-market purchase or sale.
STANDARD BIOTOOLS INC. President & CEO Michael Egholm reported a tax-related share disposition. On May 20, 2026, 97,626 shares of common stock were withheld to satisfy tax withholding obligations arising from the vesting of previously granted restricted stock units. These grants were originally awarded on May 20, 2024, March 21, 2025 and March 20, 2026. After this withholding, Egholm directly holds 6,597,956 shares of common stock, indicating this was a compensation- and tax-driven event rather than an open-market trade.
MAK Capital and related entities reported beneficial ownership of 26,172,626 shares of Standard BioTools Inc. common stock, representing 6.7% of the class. The filing states the share count is as of 05/15/2026 and references 390,368,119 shares outstanding as of May 4, 2026.
The Schedule 13G/A lists shared voting and dispositive power over the 26,172,626 shares and identifies MAK Capital Fund LP, MAK Capital One L.L.C., and Michael A. Kaufman as reporting persons. Signatures are dated 05/15/2026.
Standard BioTools Amendment No. 2 to a Schedule 13G/A: Viking Global Investors and affiliated entities report beneficial ownership of 58,651,170 shares of Common Stock. The filing states this represents 15.0% of 390,141,000 shares outstanding as of March 31, 2026. The amendment removes David C. Ott as a reporting person effective March 31, 2026.
The disclosure breaks the position into 39,296,310 shares held through Viking Global Opportunities (VGOP) and 19,354,860 shares held through Viking Global Opportunities Drawdown (VGOD), and shows shared voting and dispositive power across the listed Viking entities and two executive committee members.